NVAX: SEC Form 8-K filed by Novavax Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for NVAX
Across the 21 sessions after earlier NVAX headlines, the stock closed higher 12 times and lower 9 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NVAX | SPY |
|---|---|---|---|
| Oct 29, 2026 | Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europeand 1 other headline that session | +1.5% | -0.4% |
| Sep 3, 2026 | Novavax to Participate in September Investor Conferences | +0.2% | +1.0% |
| Aug 28, 2026 | Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season | +2.3% | -0.2% |
| Aug 6, 2026 | Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | +0.5% | -0.2% |
| Jul 30, 2026 | Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026 | +1.4% | +1.7% |
| Jun 2, 2026 | Novavax to Participate in 2026 Jefferies Global Healthcare Conference | -2.9% | +0.1% |
Quantisnow market dataNASDAQ
NVAX
Novavax Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for NVAX
Full NVAX profile on Quantisnow Follow NVAX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time